Opposing effects of anti-activation-inducible lymphocyte-immunomodulatory molecule/inducible costimulator antibody on the development of acute versus chronic graft-versus-host disease

Journal of Immunology

Volumn 167, Issue 10, 2001, Pages 5741-5748

  Ogawa, S H ^a   Nagamatsu, G ^a   Watanabe, M ^a   Watanabe, S ^a   Hayashi, T ^a   Horita, S ^a   Nitta, K ^a   Nihei, H ^a   Tezuka, K ^a   Abe, R ^a  

^a TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI ACTIVATION INDUCIBLE LYMPHOCYTE IMMUNOMODULATORY MOLECULE; CD28 ANTIGEN; CD86 ANTIGEN; IMMUNOMODULATING AGENT; INDUCIBLE COSTIMULATOR ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ACUTE DISEASE; ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIGEN RECOGNITION; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; CHIMERA; CHRONIC DISEASE; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; IMMUNOMODULATION; IMMUNOPATHOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0035889922     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.10.5741     Document Type: Article

References (57)

1. The Th1/Th2 balance in autoimmunity
2. Induction of Th1 and Th2 CD4+ T cell responses: The alternative approaches
3. - T cells
4. The paradigm of Th1 and Th2 cytokines: Its relevance to autoimmunity and allergy
5. The role of chemokine receptors in primary, effector, and memory immune responses
6. How the MHC selects Th1/Th2 immunity
7. The antigen dose determines T helper subset development by regulation of CD40 ligand
8. T cell activation and polarization by DC1 and DC2
9. Reciprocal control of T helper cell and dendritic cell differentiation
10. Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis
11. CD4 T cell cytokine differentiation: The B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1
12. LFA-1 interaction with ICAM-1 and ICAM-2 regulates Th2 cytokine production
13. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation
14. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2
15. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system
16. CD28 dependence of T cell differentiation to IL-4 production varies with the particular type 2 immune response
17. B7-CD28/CTLA-4 costimulatory pathways are required for the development of T helper cell 2-mediated allergic airway responses to inhaled antigens
18. Stat6 activation and Th2 cell differentiation [correction of proliferation] driven by CD28 [correction CD28 signals]
19. CD28 costimulation promotes the production of Th2 cytokines
20. CD28 costimulation accelerates IL-4 receptor sensitivity and IL-4-mediated Th2 differentiation
21. Acute graft-versus-host reaction can be aborted by blockade of costimulatory molecules
22. Induction of unresponsiveness and impaired T cell expansion by staphylococcal enterotoxin B in CD28-deficient mice
23. CD28 knockout mice as a useful clue to examine the pathogenesis of chronic graft-versus-host reaction
24. Protection against lethal toxic shock by targeted disruption of the CD28 gene
25. Toxic shock syndrome toxin-1-induced death is prevented by CTLA4Ig
26. ICOS is an inducible T-cell costimulator structurally and functionally related to CD28
27. B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFα
28. Molecular cloning and characterization of murine ICOS and identification of B7h as ICOS ligand
29. T-cell co-stimulation through B7RP-1 and ICOS
30. Characterization of a new human B7-related protein: B7RP-1 is the ligand to the co-stimulatory protein ICOS
31. Cutting edge: Identification of GL50, a novel B7-like protein that functionally binds to ICOS receptor
32. LICOS, a primordial costimulatory ligand?
33. - T cells
34. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses
35. ICOS co-stimulatory receptor is essential for T-cell activation and function
36. ICOS is critical for CD40-mediated antibody class switching
37. ICOS is essential for effective T-helper-cell responses
38. AILIM/ICOS: A novel lymphocyte adhesion molecule
39. Graft-versus-host reactions: Clues to the etiopathology of a spectrum of immunologic diseases
40. + T cells
41. A radioreceptor binding assay for platelet-activating factor (PAF) using membranes from CHO cells expressing human PAF receptor
42. Preferential dependence of autoantibody production in murine lupus on CD86 costimulatory molecule
43. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation
44. Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation
45. Studies on murine IgE with monoclonal antibodies. I. Characterization of rat monoclonal anti-IgE antibodies and the use of these antibodies for determinations of serum IgE levels and for anaphylactic reactions
46. A sensitive ELISPOT assay to detect low-frequency human T lymphocytes
47. T-cell interactions in autoimmunity: Insights from a murine model of graft-versus-host disease
48. Murine chronic graft-versus-host disease as a model for lupus nephritis
49. 1 mice
50. Immunodeficiency in graft-versus-host disease. I. Mechanism of immune suppression
51. The immune system: Effector and target of graft-versus-host disease
52. Long-term human B cell lines dependent on interleukin-4 and antibody to CD40
53. Cutting edge: The related molecules CD28 and inducible costimulator deliver both unique and complementary signals required for optimal T cell activation
54. Inducible costimulator protein (ICOS) controls T helper cell subset polarization after virus and parasite infection
55. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD
56. AILIM/ICOS: Its expression and functional analysis with monoclonal antibodies